<div id="readability-page-1"><div><ul> <li>Milestone Pharmaceuticals recently received U.S. Food and Drug Administration approval for CARDAMYST (etripamil) nasal spray, its first commercial product for at-home conversion of acute symptomatic paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults, with retail availability targeted for early 2026.</li> <li>This is the first new FDA-approved PSVT treatment in over 30 years and introduces a self-administered, out-of-hospital option for more than two million affected Americans, potentially changing how these arrhythmia episodes are managed.</li> <li>We’ll now examine how FDA approval of CARDAMYST as an at-home PSVT treatment reshapes Milestone Pharmaceuticals’ investment narrative.</li> </ul><p>The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</p><h2>What Is Milestone Pharmaceuticals' Investment Narrative?</h2><p>For Milestone, the big picture now hinges on whether CARDAMYST can evolve the company from a cash-burning developer into a commercially credible cardiovascular player. FDA approval removes the binary PSVT regulatory overhang and, in the near term, shifts the key catalysts to launch execution, payer coverage, and any early prescription traction as retail availability approaches in early 2026. The announcement has already refocused market debate: instead of asking “if” CARDAMYST reaches patients, investors are asking “how effectively” and “how fast,” especially given Milestone’s lack of revenue to date and a share price that still trades well below consensus targets. At the same time, the approval heightens existing risks around funding ongoing losses, potential dilution, and the company’s ability to support both a commercial rollout and its AFib-RVR program with limited resources.</p><p> However, investors also need to weigh how Milestone funds launch and pipeline commitments from here.  Despite retreating, Milestone Pharmaceuticals' shares might still be trading above their fair value and there could be some more downside. Discover how much.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dcd9838-5572-4f86-a779-654c718fddbf/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/6dcd9838-5572-4f86-a779-654c718fddbf/chart/quote-price"/><figcaption>MIST 1-Year Stock Price Chart</figcaption></figure><p> The Simply Wall St Community’s five fair value estimates span roughly US$5.68 to US$56.79 per share, reflecting sharply different expectations. With CARDAMYST now approved yet Milestone still loss making and highly valued on book, you are seeing how widely opinions can differ and why it helps to test your own view against multiple perspectives.</p><p>Explore 5 other fair value estimates on Milestone Pharmaceuticals - why the stock might be a potential multi-bagger!</p><h2>Build Your Own Milestone Pharmaceuticals Narrative</h2><p>Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.</p><ul><li>A great starting point for your Milestone Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.</li><li>Our free Milestone Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Milestone Pharmaceuticals' overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Uncover the next big thing with financially sound penny stocks that balance risk and reward.</li><li>These 10 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 33 best rare earth metal stocks of the very few that mine this essential strategic resource.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

MIST

<p>Milestone Pharmaceuticals' shares dropped 16.3% after FDA approval of CARDAMYST, a nasal spray for at-home PSVT treatment. This marks the first new PSVT treatment in over 30 years, potentially changing arrhythmia management for over two million Americans. The approval shifts focus to launch execution, payer coverage, and prescription traction as retail availability nears in 2026. Despite approval, concerns remain about funding, dilution, and commercial rollout capabilities, with varied stock value estimates reflecting differing investor expectations.</p>

Milestone Pharmaceuticals (MIST) Is Down 16.3% After First-in-Decades At-Home PSVT Drug Approval - Has The Bull Case Changed?